| 000 | 01728 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250517154333.0 | ||
| 264 | 0 | _c20170914 | |
| 008 | 201709s 0 0 eng d | ||
| 022 | _a1932-6203 | ||
| 024 | 7 |
_a10.1371/journal.pone.0177364 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDe Groot, S | |
| 245 | 0 | 0 |
_aPotential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments. _h[electronic resource] |
| 260 |
_bPloS one _c2017 |
||
| 300 |
_ae0177364 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xeconomics |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xdrug therapy |
| 650 | 0 | 4 | _aCost of Illness |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIndoles _xeconomics |
| 650 | 0 | 4 |
_aKidney Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Metastasis |
| 650 | 0 | 4 | _aNetherlands |
| 650 | 0 | 4 |
_aPyrroles _xeconomics |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 | _aRegistries |
| 650 | 0 | 4 | _aRegression Analysis |
| 650 | 0 | 4 | _aSunitinib |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aBlommestein, H M | |
| 700 | 1 | _aRedekop, W K | |
| 700 | 1 | _aSleijfer, S | |
| 700 | 1 | _aKiemeney, L A L M | |
| 700 | 1 | _aOosterwijk, E | |
| 700 | 1 | _aUyl-de Groot, C A | |
| 773 | 0 |
_tPloS one _gvol. 12 _gno. 5 _gp. e0177364 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1371/journal.pone.0177364 _zAvailable from publisher's website |
| 999 |
_c27197644 _d27197644 |
||